## Abstract We studied 20 patients with cervical dystonia who had started to respond poorly to botulinum toxin A (BTXA) injections after an initial good response. All patients had extensor digitorum brevis (EDB) tests performed in addition to BTXA immunoprecipition assay (IPA) and mouse bioassay (M
Extensor digitorum brevis test and resistance to botulinum toxin type A
β Scribed by Paul H. Gordon; Clifton L. Gooch; Paul E. Greene
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 63 KB
- Volume
- 26
- Category
- Article
- ISSN
- 0148-639X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract To evaluate changes occurring in the neuromuscular junction after injection with botulinum neurotoxin type A (BoTx), three healthy volunteers were injected with 10 U BoTx in the right extensor digitorum brevis muscle. In agreement with previous observations, amplitude of compound muscle
## Abstract To determine whether the potency of botulinum toxin A (BTA) decreases after being reconstituted with normal saline and stored in refrigerator, we injected one side of the extensor digitorum brevis muscle with 2.5 units of botulinum toxin A that had been immediately reconstituted with sa
## Abstract Between 1984 and 1992, 559 patients with torticollis were treated with botulinum toxin type A (btx) injections. Twentyβfour of these 559 patients (4.3%) had serological evidence of antibodies to btx by mouse neutralization assay. Some of the 559 patients had only one or two injection se
## Abstract Botulinum toxin (BTX) injection is considered the treatment of choice for patients with cervical dystonia (torticollis). We conducted a pilot, openβlabel, doseβescalation study with BTX type B in 12 patients who no longer responded clinically to injections with BTX type A. At the doses
## Abstract Approximately 5 to 10% of patients with cervical, segmental or multifocal dystonia receiving repetitive local injections with botulinum toxin A (BTX A) are estimated to develop secondary loss of treatment benefit (nonresponding) because of the formation of circulating serum antibodies a